背景:防御素招募富含亮氨酸重复序列的G蛋白偶联受体6阳性(Lgr6+)干细胞,最终再生新的基底干细胞,健康的角质形成细胞,和新生的毛囊.因此,防御素是一个令人兴奋的,逆转皮肤老化的新疗法。
方法:这是一个多中心,prospective,开放标签临床试验。二十个健康的受试者,45~80岁的FitzpatrickII~IV型皮肤患者被纳入研究.将含有α-防御素5和β-防御素3的皮肤护理方案每天两次应用于面部,持续12周。这种皮肤护理方案含有比已经研究的更高的防御素百分比。7所有参与者在基线时接受成像,第30天,第60天和第90天。主要终点包括Fitzpatrick-Goldman皱纹量表的研究者评分和眶周皱纹改善百分比,松弛,色素沉着,红斑,纹理,和光芒。次要终点是研究者全球美学改善评分(GAIS),主题GAIS,和研究者对耐受性的评估。最终受试者问卷在第90天完成。结果:基于Fitzpatrick-Goldman皱纹量表,从基线至第90天,在起皱和弹性变形方面均有统计学显著改善.在90天的随访中,30%的受试者在医师GAIS上被评价为改善,50%的受试者被评价为改善。在皮肤质量的各个方面都有改善,包括皱纹,松弛,色素异常,红斑,纹理,和光芒。结论:包含增加浓度的α-防御素5和β-防御素3的增强配方是一种安全有效的局部治疗方法,可用于治疗眶周畸形。
背景:HartmanN,忠诚的J,TaubA,etal.α和β防御素皮肤护理方案改善眼周皱纹的临床试验。J药物Dermatol.2023年;22(9):874-880。doi:10.36849/JDD.7184。
BACKGROUND: Defensins recruit leucine-rich repeat-containing G protein-coupled receptor 6 positive (Lgr6+) stem cells which ultimately regenerate new basal stem cells, healthy keratinocytes, and nascent hair follicles. Thus, defensins are an exciting, novel therapy for the reversal of skin aging.
METHODS: This is a multicenter, prospective, open-label clinical
trial. Twenty healthy subjects, aged 45-80, with Fitzpatrick skin types II-IV were enrolled in the
study. A skin care regimen containing alpha-defensin 5 and beta-defensin 3 were applied to the face twice daily for 12 weeks. This skin care regimen contains a greater percentage of defensins than that already studied.7 All participants underwent imaging at baseline, day 30, day 60, and day 90. Primary endpoints included investigator scoring on the Fitzpatrick-Goldman wrinkle scale and percent improvement in periorbital wrinkles, laxity, pigmentation, erythema, texture, and radiance. Secondary endpoints were investigator Global Aesthetic Improvement Score (GAIS), subject GAIS, and investigator assessment of tolerability. A final subject questionnaire was completed on day 90. Results: Based on the Fitzpatrick-Goldman wrinkle scale, a statistically significant improvement was noted in both wrinkling and elastosis from baseline to day 90. 30% of subjects were rated as much improved and 50% of subjects were rated as improved on the physician GAIS at the 90 day follow up. Improvements were noted in all aspects of skin quality including wrinkles, laxity, dyschromia, erythema, texture, and radiance. Conclusion: The enhanced formula containing increased concentrations of alpha-defensin 5 and beta-defensin 3 is a safe and efficacious topical therapy for the treatment of periorbital rhytids.
BACKGROUND: Hartman N, Loyal J, Taub A, et al. Clinical
trial of alpha and beta defensin skin care regimen for improvement of periocular wrinkles. J Drugs Dermatol. 2023;22(9):874-880. doi:10.36849/JDD.7184.